Cellular heterogeneity profiling by hyaluronan probes reveals an invasive but slow-growing breast tumor subset

Proceedings of the National Academy of Sciences of the United States of America

Volumn 111, Issue 17, 2014, Pages

  Veiseh, Mandana ^a   Kwon, Daniel H ^a   Borowsky, Alexander D ^b,c   Tolg, Cornelia ^d   Leong, Hon S ^d   Lewis, John D ^e   Turley, Eva A ^d,f   Bissell, Mina J ^a  

^a LAWRENCE BERKELEY NATIONAL LABORATORY   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d LONDON HEALTH SCIENCES CENTRE   (Canada)

^e UNIVERSITY OF ALBERTA   (Canada)

^f UNIVERSITY OF WESTERN ONTARIO   (Canada)

Author keywords

Heterogeneity index; Hyaluronan binding; Tumor cell heterogeneity

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; HERMES ANTIGEN; HYALURONIC ACID; INTERLEUKIN 2 RECEPTOR; MESSENGER RNA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; BREAST TUMOR; CANCER MORPHOLOGY; CELL HETEROGENEITY; CHICKEN; CHORIOALLANTOIS; CONTROLLED STUDY; DISEASE SEVERITY; EXTRAVASATION; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IN VIVO STUDY; INTERNALIZATION; LUNG METASTASIS; LYMPH VESSEL METASTASIS; MICROMETASTASIS; MOLECULAR PROBE; MOUSE; NONHUMAN; PARTICLE SIZE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SURVIVAL RATE; TUMOR GROWTH; TUMOR INVASION; TUMOR MICROENVIRONMENT; TUMOR XENOGRAFT;

HETEROGENEITY INDEX; HYALURONAN BINDING; TUMOR CELL HETEROGENEITY;

ANIMALS; ANTIGENS, CD44; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; CHICKENS; CHORIOALLANTOIC MEMBRANE; COMPUTER SYSTEMS; EXTRACELLULAR MATRIX PROTEINS; FEMALE; FLUORESCENCE; HUMANS; HYALURONIC ACID; MICE; MICE, SCID; MOLECULAR PROBES; NEOPLASM INVASIVENESS; PHENOTYPE; TRIPLE NEGATIVE BREAST NEOPLASMS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84899636270     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1402383111     Document Type: Article

References (82)

1. Baumgarten SC, Frasor J (2012) Minireview: Inflammation: An instigator of more aggressive estrogen receptor (ER) positive breast cancers. Mol Endocrinol 26(3): 360-371.
2. Boudreau A, van't Veer LJ, Bissell MJ (2012) An "elite hacker": Breast tumors exploit the normal microenvironment program to instruct their progression and biological diversity. Cell Adhes Migr 6(3):236-248.
3. Marusyk A, Almendro V, Polyak K (2012) Intra-tumour heterogeneity: A looking glass for cancer? Nat Rev Cancer 12(5):323-334.
4. Metzger-Filho O, et al. (2012) Dissecting the heterogeneity of triple-negative breast cancer. J Clin Oncol 30(15):1879-1887.
5. Liu J, Li S, Dunker AK, Uversky VN (2012) Molecular profiling: An essential technology enabling personalized medicine in breast cancer. Curr Drug Targets 13(4):541-554.
6. Petersen OW, Gudjonsson T, Villadsen R, Bissell MJ, Rønnov-Jessen L (2003) Epithelial progenitor cell lines as models of normal breast morphogenesis and neoplasia. Cell Prolif 36(Suppl 1):33-44.
7. Kim J, et al. (2012) Tumor initiating but differentiated luminal-like breast cancer cells are highly invasive in the absence of basal-like activity. Proc Natl Acad Sci USA 109(16): 6124-6129.
8. Pepin F, et al. (2012) Gene expression profiling of microdissected breast cancer microvasculature identifies distinct tumor vascular subtypes. Breast Cancer Res 14(4):R120.
9. Kabos P, et al. (2012) Patient-derived luminal breast cancer xenografts retain hormone receptor heterogeneity and help define unique estrogen-dependent gene signatures. Breast Cancer Res Treat 135(2):415-432.
10. Jeschke J, et al. (2012) Biomarkers for detection and prognosis of breast cancer identified by a functional hypermethylome screen. Epigenetics (7):701-709.
11. Dedeurwaerder S, Fumagalli D, Fuks F (2011) Unravelling the epigenomic dimension of breast cancers. Curr Opin Oncol 23(6):559-565.
12. Prat A, Ellis MJ, Perou CM (2012) Practical implications of gene-expression-based assays for breast oncologists. Nat Rev Clin Oncol 9(1):48-57.
13. Irshad S, Ellis P, Tutt A (2011) Molecular heterogeneity of triple-negative breast cancer and its clinical implications. Curr Opin Oncol 23(6):566-577.
14. Burrell RA, et al. (2010) Targeting chromosomal instability and tumour heterogeneity in HER2-positive breast cancer. J Cell Biochem 111(4):782-790.
15. Rakha E, Reis-Filho JS (2009) Basal-like breast carcinoma: From expression profiling to routine practice. Arch Pathol Lab Med 133(6):860-868.
16. Potapenko IO, et al. (2010) Glycan gene expression signatures in normal and malignant breast tissue; possible role in diagnosis and progression. Mol Oncol 4(2):98-118.
17. Rabinovich GA, van Kooyk Y, Cobb BA (2012) Glycobiology of immune responses. Ann N Y Acad Sci 1253:1-15.
18. Miyamoto S (2006) Clinical applications of glycomic approaches for the detection of cancer and other diseases. Curr Opin Mol Ther 8(6):507-513.
19. Jiang D, Liang J, Noble PW (2011) Hyaluronan as an immune regulator in human diseases. Physiol Rev 91(1):221-264.
20. Veiseh M, Turley EA (2011) Hyaluronan metabolism in remodeling extracellular matrix: Probes for imaging and therapy of breast cancer. Integrative Biol 3(4):304-315.
21. Hamilton SR, et al. (2009) Pharmacokinetics and pharmacodynamics of hyaluronan infused into healthy human volunteers. Open Drug Metab 3:43-55.
22. Maxwell CA, McCarthy J, Turley E (2008) Cell-surface and mitotic-spindle RHAMM: Moonlighting or dual oncogenic functions? J Cell Sci 121(Pt 7):925-932.
23. Sironen RK, et al. (2011) Hyaluronan in human malignancies. Exp Cell Res 317(4): 383-391.
24. Corte MD, et al. (2010) Analysis of the expression of hyaluronan in intraductal and invasive carcinomas of the breast. J Cancer Res Clin Oncol 136(5):745-750.
25. Bollyky PL, Bogdani M, Bollyky JB, Hull RL, Wight TN (2012) The role of hyaluronan and the extracellular matrix in islet inflammation and immune regulation. Curr Diab Rep 12(5):471-480.
26. Erickson M, Stern R (2012) Chain gangs: New aspects of hyaluronan metabolism. Biochem Res Int 2012:893947.
27. DeAngelis PL (2012) Glycosaminoglycan polysaccharide biosynthesis and production: Today and tomorrow. Appl Microbiol Biotechnol 94(2):295-305.
28. Afratis N, et al. (2012) Glycosaminoglycans: Key players in cancer cell biology and treatment. FEBS J 279(7):1177-1197.
29. Tolg C, et al. (2012) A RHAMM mimetic peptide blocks hyaluronan signaling and reduces inflammation and fibrogenesis in excisional skin wounds. Am J Pathol 181(4): 1250-1270.
30. Gao F, et al. (2010) Hyaluronan oligosaccharides promote excisional wound healing through enhanced angiogenesis. Matrix Biol 29(2):107-116.
31. Veiseh M, et al. (2012) Imaging of homeostatic, neoplastic, and injured tissues by HA-based probes. Biomacromolecules 13(1):12-22.
32. Toole BP (2004) Hyaluronan: From extracellular glue to pericellular cue. Nat Rev Cancer 4(7):528-539.
33. Turley EA, Naor D (2012) RHAMM and CD44 peptides-analytic tools and potential drugs. Front Biosci 17:1775-1794.
34. Wang A, de la Motte C, Lauer M, Hascall V (2011) Hyaluronan matrices in pathobiological processes. FEBS J 278(9):1412-1418.
35. Neri P, Bahlis NJ (2012) Targeting of adhesion molecules as a therapeutic strategy in multiple myeloma. Curr Cancer Drug Targets 12(7):776-796.
36. Orian-Rousseau V (2010) CD44, a therapeutic target for metastasising tumours. Eur J Cancer 46(7):1271-1277.
37. Auvinen P, et al. (2013) Increased hyaluronan content and stromal cell CD44 associate with HER2 positivity and poor prognosis in human breast cancer. Int J Cancer 132(3): 531-539.
38. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF (2003) Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA100(7):3983-3988.
39. Shipitsin M, et al. (2007) Molecular definition of breast tumor heterogeneity. Cancer Cell 11(3):259-273.
40. Idowu MO, et al. (2012) CD44(+)/CD24(-/low) cancer stem/progenitor cells are more abundant in triple-negative invasive breast carcinoma phenotype and are associated with poor outcome. Hum Pathol 43(3):364-373.
41. Wang C, et al. (1998) The overexpression of RHAMM, a hyaluronan-binding protein that regulates ras signaling, correlates with overexpression of mitogen-activated protein kinase and is a significant parameter in breast cancer progression. Clin Cancer Res 4(3):567-576.
42. Kalmyrzaev B, Pharoah PD, Easton DF, Ponder BA, Dunning AM; SEARCH Team (2008) Hyaluronan-mediated motility receptor gene single nucleotide polymorphisms and risk of breast cancer. Cancer Epidemiol Biomarkers Prev 17(12):3618-3620.
43. Maxwell CA, et al.; HEBON; EMBRACE; SWE-BRCA; BCFR; GEMO Study Collaborators; kConFab (2011) Interplay between BRCA1 and RHAMM regulates epithelial apicobasal polarization and may influence risk of breast cancer. PLoS Biol 9(11):e1001199.
44. Kristensen VN, et al. (2012) Integrated molecular profiles of invasive breast tumors and ductal carcinoma in situ (DCIS) reveal differential vascular and interleukin signaling. Proc Natl Acad Sci USA 109(8):2802-2807.
45. Sørlie T, et al. (2001) Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 98(19):10869-10874.
46. Perou CM, et al. (2000) Molecular portraits of human breast tumours. Nature 406(6797):747-752.
47. Neve RM, et al. (2006) A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell 10(6):515-527.
48. Wang SJ, Saadi W, Lin F, Minh-Canh Nguyen C, Li Jeon N (2004) Differential effects of EGF gradient profiles on MDA-MB-231 breast cancer cell chemotaxis. Exp Cell Res 300(1):180-189.
49. Ye Q, Kantonen S, Gomez-Cambronero J (2013) Serum deprivation confers the MDAMB-231 breast cancer line with an EGFR/JAK3/PLD2 system that maximizes cancer cell invasion. J Mol Biol 425(4):755-766.
50. Gelmon K, et al. (2012) Targeting triple-negative breast cancer: Optimising therapeutic outcomes. Ann Oncol 23(9):2223-2234.
51. Tester AM, et al. (2004) Pro-matrix metalloproteinase-2 transfection increases orthotopic primary growth and experimental metastasis of MDA-MB-231 human breast cancer cells in nude mice. Cancer Res 64(2):652-658.
52. Marshall JC, et al. (2012) Effect of inhibition of the lysophosphatidic acid receptor 1 on metastasis and metastatic dormancy in breast cancer. J Natl Cancer Inst 104(17): 1306-1319.
53. Sheridan C, et al. (2006) CD44+/CD24-breast cancer cells exhibit enhanced invasive properties: An early step necessary for metastasis. Breast Cancer Res 8(5):R59.
54. Hamilton SR, et al. (2007) The hyaluronan receptors CD44 and Rhamm (CD168) form complexes with ERK1,2 that sustain high basal motility in breast cancer cells. J Biol Chem 282(22):16667-16680.
55. Shapiro SS, Wilk MB (1965) An analysis of variance test for normality (complete samples). Biometrika 52(3/4):591-611.
56. Lee GY, Kenny PA, Lee EH, Bissell MJ (2007) Three-dimensional culture models of normal and malignant breast epithelial cells. Nat Methods 4(4):359-365.
57. Wang F, et al. (2002) Phenotypic reversion or death of cancer cells by altering signaling pathways in three-dimensional contexts. J Natl Cancer Inst 94(19):1494-1503.
58. Bourguignon LY, Spevak CC, Wong G, Xia W, Gilad E (2009) Hyaluronan-CD44 interaction with protein kinase C(epsilon) promotes oncogenic signaling by the stem cell marker Nanog and the Production of microRNA-21, leading to down-regulation of the tumor suppressor protein PDCD4, anti-apoptosis, and chemotherapy resistance in breast tumor cells. J Biol Chem 284(39):26533-26546.
59. Kim Y, et al. (2008) CD44-epidermal growth factor receptor interaction mediates hyaluronic acid-promoted cell motility by activating protein kinase C signaling involving Akt, Rac1, Phox, reactive oxygen species, focal adhesion kinase, and MMP-2. J Biol Chem 283(33):22513-22528.
60. Naor D, Nedvetzki S, Golan I, Melnik L, Faitelson Y (2002) CD44 in cancer. Crit Rev Clin Lab Sci 39(6):527-579.
61. Ribatti D (2010) The chick embryo chorioallantoic membrane as an in vivo assay to study antiangiogenesis. Pharmaceuticals 3(3):482-513.
62. Deryugina EI, Quigley JP (2008) Chick embryo chorioallantoic membrane model systems to study and visualize human tumor cell metastasis. Histochem Cell Biol 130(6): 1119-1130.
63. Zijlstra A, Lewis J, Degryse B, Stuhlmann H, Quigley JP (2008) The inhibition of tumor cell intravasation and subsequent metastasis via regulation of in vivo tumor cell motility by the tetraspanin CD151. Cancer Cell 13(3):221-234.
64. Leong HS, Chambers AF, Lewis JD (2012) Assessing cancer cell migration and metastatic growth in vivo in the chick embryo using fluorescence intravital imaging. Methods Mol Biol 872:1-14.
65. Heppner GH, Miller BE (1983) Tumor heterogeneity: Biological implications and therapeutic consequences. Cancer Metastasis Rev 2(1):5-23.
66. Nowell PC (1976) The clonal evolution of tumor cell populations. Science 194(4260): 23-28.
67. Simpson-Herren L, Noker PE, Wagoner SD (1988) Variability of tumor response to chemotherapy. II. Contribution of tumor heterogeneity. Cancer Chemother Pharmacol 22(2):131-136.
68. Dexter DL, Leith JT (1986) Tumor heterogeneity and drug resistance. J Clin Oncol 4(2): 244-257.
69. Moore NM, Kuhn NZ, Hanlon SE, Lee JS, Nagahara LA (2011) De-convoluting cancer's complexity: Using a 'physical sciences lens' to provide a different (clearer) perspective of cancer. Preface. Phys Biol 8(1):010302.
70. Gupta PB, et al. (2011) Stochastic state transitions give rise to phenotypic equilibrium in populations of cancer cells. Cell 146(4):633-644.
71. Toole BP, Slomiany MG (2008) Hyaluronan: A constitutive regulator of chemoresistance and malignancy in cancer cells. Semin Cancer Biol 18(4):244-250.
72. Golshani R, et al. (2008) Hyaluronic acid synthase-1 expression regulates bladder cancer growth, invasion, and angiogenesis through CD44. Cancer Res 68(2):483-491.
73. Bissell MJ, Kenny PA, Radisky DC (2005) Microenvironmental regulators of tissue structure and function also regulate tumor induction and progression: The role of extracellular matrix and its degrading enzymes. Cold Spring Harb Symp Quant Biol 70:343-356.
74. Curtis MW, Sharma S, Desai TA, Russell B (2010) Hypertrophy, gene expression, and beating of neonatal cardiac myocytes are affected by microdomain heterogeneity in 3D. Biomed Microdevices 12(6):1073-1085.
75. Khaing ZZ, Schmidt CE (2012) Advances in natural biomaterials for nerve tissue repair. Neurosci Lett 519(2):103-114.
76. Briand P, Nielsen KV, Madsen MW, Petersen OW (1996) Trisomy 7p and malignant transformation of human breast epithelial cells following epidermal growth factor withdrawal. Cancer Res 56(9):2039-2044.
77. Petersen OW, Rønnov-Jessen L, Howlett AR, Bissell MJ (1992) Interaction with basement membrane serves to rapidly distinguish growth and differentiation pattern of normal and malignant human breast epithelial cells. Proc Natl Acad Sci USA 89(19): 9064-9068.
78. Weaver VM, Howlett AR, Langton-Webster B, Petersen OW, Bissell MJ (1995) The development of a functionally relevant cell culture model of progressive human breast cancer. Semin Cancer Biol 6(3):175-184.
79. Debnath J, Muthuswamy SK, Brugge JS (2003) Morphogenesis and oncogenesis of MCF-10A mammary epithelial acini grown in three-dimensional basement membrane cultures. Methods 30(3):256-268.
80. Kemp MM, et al. (2009) Synthesis of gold and silver nanoparticles stabilized with glycosaminoglycans having distinctive biological activities. Biomacromolecules 10(3): 589-595.
81. Leong HS, et al. (2010) Intravital imaging of embryonic and tumor neovasculature using viral nanoparticles. Nat Protoc 5(8):1406-1417.
82. Arpaia E, et al. (2012) The interaction between caveolin-1 and Rho-GTPases promotes metastasis by controlling the expression of alpha5-integrin and the activation of Src, Ras and Erk. Oncogene 31(7):884-896.